医学
甲状腺髓样癌
内科学
髓腔
突变体
凡德他尼
甲状腺癌
肿瘤科
癌症
癌症研究
生物
索拉非尼
遗传学
基因
肝细胞癌
作者
Julien Hadoux,Rossella Elisei,Marcia S. Brose,Ana O. Hoff,Bruce G. Robinson,Ming Gao,Barbara Jarząb,П. А. Исаев,Kateřina Kopečková,Jonathan Wadsley,Dagmar Führer,Bhumsuk Keam,Stéphane Bardet,Eric J. Sherman,Makoto Tahara,Mimi I. Hu,Ravinder Singh,Yan Lin,Victoria Soldatenkova,Jennifer Wright
标识
DOI:10.1056/nejmoa2309719
摘要
Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.).
科研通智能强力驱动
Strongly Powered by AbleSci AI